Literature DB >> 8264136

Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus.

K Hirata1, S Kikuchi, K Saku, S Jimi, B Zhang, S Naito, H Hamaguchi, K Arakawa.   

Abstract

We studied the quantitative and qualitative characteristics of lipoprotein(a) [Lp(a)] as a function of apolipoprotein(a) [apo(a)] phenotypes in 152 patients (123 males, 29 females) undergoing maintenance hemodialysis (HD) with or without diabetes mellitus (DM), in 101 patients with diabetes mellitus without hemodialysis (58 males, 43 females), and in 421 normal controls (333 males, 88 females). Serum Lp(a) levels were significantly (P < 0.01) higher in patients than in controls (26.2 +/- 18.3 mg/dl in HD with DM, 26.4 +/- 22.0 mg/dl in HD without DM, 27.1 +/- 27.3 mg/dl in DM without HD, and 14.9 +/- 13.7 mg/dl in controls, respectively). Apo(a) phenotyping was performed by a sensitive, high resolution technique using SDS-agarose/gradient (3 to 6%) PAGE. In normal controls, the molecular weights of apo(a) isoforms were inversely correlated with plasma Lp(a) levels, and the same tendency was found in patients who were undergoing hemodialysis and/or who had diabetes mellitus. We assumed the differences in apo(a) phenotypes detectable with our method reflected consecutive differences in molecular weights of apo(a). The results of an analysis of covariance and a least square means comparison indicated that the regression lines between serum Lp(a) levels [log Lp(a)] and apo(a) phenotypes in patient groups were significantly (P < 0.01) elevated for every apo(a) phenotype, as compared to the regression line of the control group. Even after the low molecular weight apo(a) phenotypes (A1-A8) were omitted, the same tendency was observed. However, no differences were observed between the patient groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8264136     DOI: 10.1038/ki.1993.349

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

1.  Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine.

Authors:  V Mooser; S M Marcovina; A L White; H H Hobbs
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

2.  Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in the families of NIDDM patients.

Authors:  K Hirata; K Saku; S Jimi; S Kikuchi; H Hamaguchi; K Arakawa
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

Review 3.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

4.  Lipoprotein(a) and cardiovascular disease in diabetic patients.

Authors:  Qibin Qi; Lu Qi
Journal:  Clin Lipidol       Date:  2012-08

Review 5.  The role of lipoprotein (a) in chronic kidney disease.

Authors:  Jemma C Hopewell; Richard Haynes; Colin Baigent
Journal:  J Lipid Res       Date:  2018-01-29       Impact factor: 5.922

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.